1. Home
  2. CCCC vs BNR Comparison

CCCC vs BNR Comparison

Compare CCCC & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.15

Market Cap

208.4M

Sector

Health Care

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$34.50

Market Cap

216.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCCC
BNR
Founded
2015
2014
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.4M
216.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CCCC
BNR
Price
$2.15
$34.50
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$7.25
N/A
AVG Volume (30 Days)
1.6M
34.9K
Earning Date
02-26-2026
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$30,108,000.00
$75,749,382.00
Revenue This Year
N/A
$136.32
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.56
52 Week Low
$1.09
$2.18
52 Week High
$3.84
$41.72

Technical Indicators

Market Signals
Indicator
CCCC
BNR
Relative Strength Index (RSI) 47.25 65.43
Support Level $2.06 $29.88
Resistance Level $2.23 $41.72
Average True Range (ATR) 0.15 3.94
MACD 0.02 1.23
Stochastic Oscillator 32.99 73.17

Price Performance

Historical Comparison
CCCC
BNR

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: